VALUE Study Shares Long-term Psoriasis Treatment Data
Three-year real-world results show continued skin clearance for patients treated with risankizumab.
Updated on Oct. 16, 2026 in Asthma
Live Poll
Should patients with moderate plaque psoriasis prioritize biologic treatments over oral medications for better results?
The VALUE study released three-year real-world data at the 2026 EADV Congress in Vienna on September 30, highlighting the long-term effectiveness of risankizumab for plaque psoriasis. The findings demonstrate that patients achieving clear skin in the first year maintained these results through the three-year mark.
Why it matters
High-impact lesions on areas like the scalp, palms, or soles often necessitate early systemic intervention. These findings provide clinicians with evidence to support shared decision-making when selecting long-term biologic therapies for moderate to severe cases.
In a 25-month interim analysis of 2,639 patients, risankizumab achieved a 70.0% Dermatology Life Quality Index 0/1 rate compared to 52.9% for other biologics. Maintenance dosing for the treatment is administered every 12 weeks.
The players
EADV Congress
This is a major international medical conference focused on the latest developments and research in dermatology.
The details
The study compared risankizumab against other biologics while accounting for diverse patient comorbidities and concomitant medications. Researchers presented the data at the EADV Congress to illustrate the durability of skin clearance and patient quality of life outcomes.
Timeline
The EADV Congress in Vienna occurred from September 30 to October 3, 2026.
Health Landscape
The findings from the VALUE study extend the understanding of treatment durability in chronic autoimmune conditions. This evidence base marks a shift toward prioritizing long-term patient-reported quality of life metrics alongside traditional clinical clearance benchmarks.
Patients may find that these results support a more consistent long-term treatment plan with maintenance dosing scheduled every 12 weeks. Those suffering from high-impact lesions can use this data to discuss potential therapy switches with their dermatologists.
The takeaway
Durable skin clearance remains a primary goal for those managing moderate to severe plaque psoriasis over several years. Patients should consult their healthcare providers to determine if current biologic maintenance schedules remain optimal for their specific symptom progression.
Further reading
Learn more about the latest research in the Asthma section.
Source note: This article includes information reported by Hcplive.
Live Poll
Should patients with moderate plaque psoriasis prioritize biologic treatments over oral medications for better results?
